Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
August 31, 2021
Assignee:
Bayer HealthCare LLC
Inventors:
Alan Brooks, Richard Feldman, Jian-Ming Gu, Shaun Lippow, Shujun Yuan, Peter Bringmann
Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
August 31, 2021
Assignee:
IMMUSOFT CORPORATION
Inventors:
R. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
Type:
Grant
Filed:
May 16, 2017
Date of Patent:
August 24, 2021
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
Abstract: The invention provides a method and composition for preventing thrombosis and complications associated therewith by targeting Sf2 directly. The invention provides Sf2-deficiency or prophylactic administration of a therapeutic agent, such as a Sf2 antagonist or a Sf2 antibody, markedly reduces thrombus formation that would otherwise be caused due to surgery, immobility, genetic abnormality, cancer, trauma, or other risk factors.
Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
Type:
Grant
Filed:
October 3, 2019
Date of Patent:
August 3, 2021
Assignee:
Nepenthe Bioscience LLC
Inventors:
James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
Type:
Grant
Filed:
November 15, 2016
Date of Patent:
August 3, 2021
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Xiao-Yan Zhao, Andreas Wilmen, Christoph Freiberg, Lars Linden, Ji-Yun Kim, Subramanian Yegneswaran, Karin Regnstrom, Ursula Egner, Xinquan Wang
Abstract: Methods and pharmaceutical compositions for treating hemorrhage or bleeding are provided. The pharmaceutical compositions include an effective amount of an antifibrinolytic composition that reduces or inhibits hemorrhage or bleeding in a subject.
Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
July 20, 2021
Assignees:
The Regents of the University of California, Pfizer, Inc.
Inventors:
Thomas Mikita, Lauren K. Ely, Huilan Gao, Yun Kim, Isaac J. Rondon, Tovo David, Shaun R. Coughlin
Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
Type:
Grant
Filed:
March 23, 2017
Date of Patent:
July 13, 2021
Assignee:
Prothix B.V.
Inventors:
Péter Boross, Cafer Yildiz, Cornelis Erik Hack
Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
June 29, 2021
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
Abstract: A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
June 8, 2021
Assignee:
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
Inventors:
Bernhard Nieswandt, Sarah Beck, David Stegner
Abstract: The present disclosure provides, inter alia, anti-peripheral lymph node addressin antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
Type:
Grant
Filed:
December 30, 2008
Date of Patent:
April 6, 2021
Assignee:
Agilent Technologies, Inc.
Inventors:
Jørgen Schøller, Liselotte Brix, Henrik Pedersen
Abstract: This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
March 23, 2021
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Mark Karbarz, Pamela B. Conley, Genmin Lu
Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
March 23, 2021
Assignee:
MEDIMMUNE LIMITED
Inventors:
Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt